Anti-angiogenic therapies, by aiming at VEGF (such as sorafenib, a specific inhibitor of VEGF tyrosine kinase receptor), have been developed as a novel therapeutic strategy for HCC (20, 21). This evidence concerns the gene VEGFA and hepatocellular carcinoma.